No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EW240621P85000
- 0.12
- -0.17-58.62%
15min DelayTrading Jun 20 12:24 ET
0.12High0.05Low
0.12Open0.29Pre Close13 Volume630 Open Interest85.00Strike Price118.00Turnover55.68%IV5.15%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type-0.0696Delta0.0418Gamma894.90Leverage Ratio-0.0965Theta-0.0002Rho-62.33Eff Leverage0.0077Vega
Intraday
- 5D
- Daily
News
$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 10.47% on an annualized basis producing an average annual return of 18.64%. Currently, Edwards Lifesciences has a m
Edwards Lifesciences Stock: Is EW Underperforming the Healthcare Sector?
Investors in Edwards Lifesciences (NYSE:EW) Have Seen Favorable Returns of 42% Over the Past Five Years
Does Edwards Lifesciences Corporation (EW) Have Attractive Growth Opportunities?
Will Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Prove Temporary Given Strong Fundamentals?
It is hard to get excited after looking at Edwards Lifesciences' (NYSE:EW) recent performance, when its stock has declined 7.9% over the past three months. But if you pay close attention, you might
Express News | Watching AtriCure; Traders Circulating Unconfirmed Rumor Suggesting Edwards Lifesciences Is Said To Mull Takeover Bid For The Co
Comments
Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Edwards Lifesciences (NYSE:EW) Is Aiming To Keep Up Its Impressive ReturnsAnalysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
+17
18
Pre-Market Stock Movers
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
17
Read more